Sinopharm Group's declining ROCE trend is concerning. Increa...
Sinopharm Group's declining ROCE trend is concerning. Increased capital investment without matching sales suggests long-term plays. High current liabilities to total assets ratio introduces risk. These trends indicate Sinopharm may not be a multi-bagger.
Sinopharm Group (HKG:1099) Will Be Hoping To Turn Its Returns On Capital Around
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3178Followers
0Following
7937Visitors
Follow